Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria ...

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

A continuing medical education (CME) programme organised by the Department of Pulmonary Medicine, TB Hospital, Government ...

For treating pulmonary fibrosis, presently the pharmacological arsenal involves only two drugs, pirfenidone and nintedanib, which work to slow down the disease progression but do not completely ...

Department of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Neuroimmunology and Inflammation, Einstein Institute for Aging Research, Albert ...

In COPD, muscular atrophy is a significant risk factor for death and may prolong patients’ hospital length of stay.

“[A] chest CAT scan which the Holy Father received this afternoon … showed the onset of bilateral pneumonia that requires further pharmacological therapy,” it added. The pope ...

The effect of erdosteine on mucus rheological properties was evaluated in patients with exacerbation of COPD. [24] Patients receiving erdosteine had statistically significant reduction in sputum ...

Clinical pharmacology is a branch of biomedical science. It includes drug discovery, the study of the effects of drugs on their targets in living systems and their clinical use, as well as the ...